Longeveron Inc. (LGVN)
| Previous Close | 2.92 |
| Open | 3.72 |
| Bid | 6.74 x 1000 |
| Ask | 7.00 x 900 |
| Day's Range | 3.69 - 8.90 |
| 52 Week Range | 2.84 - 45.00 |
| Volume | |
| Avg. Volume | 10,701,290 |
| Market Cap | 130.417M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | May 14, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Motley Fool
Why Longeveron Stock Is Skyrocketing Today
Shares of Longeveron (NASDAQ: LGVN) were skyrocketing 72.9% as of 11:51 a.m. ET on Wednesday after more than doubling earlier in the day. An epic short squeeze appears to be underway. Longeveron announced on Nov. 18 that the U.S. Food and Drug Administration (FDA) granted a Rare Pediatric Disease designation to experimental drug Lomecel-B in treating a rare congenital heart defect.
- Bloomberg
Retail Traders Jump Back Into Tiny Biotechs Ahead of Holiday
(Bloomberg) -- Two tiny biotechs, ISpecimen Inc. and Longeveron Inc., are the latest to see their stocks caught up in a social media-fueled frenzy ahead of a U.S. trading holiday. Most Read from BloombergAsia’s Richest Man Looks to Walton Family Playbook on SuccessionBillionaire Family Feud Puts a Century-Old Business Empire in JeopardyThe 24-Year-Old Aiming to Dethrone Victoria’s SecretThe Winners and Losers From a Year of Ranking Covid ResilienceNew York City Is Building a Wall of Oysters to F
- GlobeNewswire
U.S. Food and Drug Administration Approves Longeveron’s Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition
Phase 2 clinical trial underway for Hypoplastic Left Heart Syndrome, which affects approximately 1,000 babies per yearMIAMI, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for Lomecel-B for the treatment of
